MedTrace Logo

Assessment of Patients Treated With JETREA® for Vitreomacular Traction

NCT02035748 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 628

Last updated 2016-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.

Conditions

  • Vitreomacular Traction
  • Vitreomacular Adhesion

Interventions

DRUG

Ocriplasmin

0.5 mg/0.2 mL solution for injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Sr Clinical Manager, Ophtha-GCRA · Alcon, a Novartis Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-09-30
Completion
2015-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02035748 on ClinicalTrials.gov